MedKoo Cat#: 584373 | Name: Satigrel

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Satigrel, also known as E 5510, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts.

Chemical Structure

Satigrel
Satigrel
CAS#111753-73-2

Theoretical Analysis

MedKoo Cat#: 584373

Name: Satigrel

CAS#: 111753-73-2

Chemical Formula: C20H19NO4

Exact Mass: 337.1314

Molecular Weight: 337.38

Elemental Analysis: C, 71.20; H, 5.68; N, 4.15; O, 18.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Satigrel; E 5510; E5510
IUPAC/Chemical Name
4-Cyano-5,5-bis(p-methoxyphenyl)-4-pentenoic acid
InChi Key
GRVCTHTXJDYIHB-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H19NO4/c1-24-17-8-3-14(4-9-17)20(16(13-21)7-12-19(22)23)15-5-10-18(25-2)11-6-15/h3-6,8-11H,7,12H2,1-2H3,(H,22,23)
SMILES Code
O=C(O)CC/C(C#N)=C(C1=CC=C(OC)C=C1)/C2=CC=C(OC)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 337.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moriwaki H, Matsumoto M, Handa N, Hashikawa K, Hori M, Nishimura T. Effect of E5510, a novel antiplatelet agent, on platelet deposition in atherothrombotic lesions: evaluation by 111In platelet scintigraphy. Nucl Med Commun. 2000 Nov;21(11):1051-8. PubMed PMID: 11192711. 2: Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB. J Biol Chem. 2000 Jan 14;275(2):883-9. PubMed PMID: 10625622. 3: Sarker KP, Abeyama K, Nishi J, Nakata M, Tokioka T, Nakajima T, Kitajima I, Maruyama I. Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor. Thromb Haemost. 1999 Sep;82(3):1071-7. PubMed PMID: 10494766. 4: Bianchi ML, Ardissino GL, Schmitt CP, Daccó V, Barletta L, Claris-Appiani A, Mehls O. No difference in intestinal strontium absorption after an oral or an intravenous 1,25(OH)2D3 bolus in normal subjects. For the European Study Group on Vitamin D in children with renal failure. J Bone Miner Res. 1999 Oct;14(10):1789-95. PubMed PMID: 10491227. 5: Reilly MP, Moran N, Meagher E, Delanty N, Cucchiara AE, Lawson JA, Catella-Lawson F. A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers. J Cardiovasc Pharmacol. 1999 Jan;33(1):12-8. PubMed PMID: 9890391. 6: Suga K, Nishigauchi K, Kume N, Kishimoto K, Matsunaga N, Fujioka K, Zempo N, Kensuke E. The effects of new platelet inhibitory drug E-5510 on platelet deposition on aortic bifurcation grafts: assessment by indium-111-oxime labeled platelet imaging. Clin Nucl Med. 1998 Jun;23(6):365-9. PubMed PMID: 9619322. 7: Esato K, Kubo Y, Yasuda K, Shigematsu H, Iwai T, Ishimaru S, Uchida H, Ishii K. Satigrel, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts. Am J Surg. 1998 Jan;175(1):56-60. PubMed PMID: 9445241. 8: Mawatari K, Komori K, Kuma S, Okazaki J, Kawasaki K, Eguchi D, Itoh H, Onohara T, Sugimachi K. The inhibition of canine vein graft intimal thickening using a newly developed antiplatelet agent. J Cardiovasc Surg (Torino). 1997 Aug;38(4):359-65. PubMed PMID: 9267344. 9: Teraoka S, Ota K, Tanabe K, Takahashi K, Toma H, Yasumura T, Yoshimura N, Oka T, Takahara S, Okuyama A, Haba T, Uchida K, Sugiyama S, Ohshima S, Sato T, Okazaki H, Morozumi K. Multicenter trial of the therapeutic effect of a newly developed antiplatelet agent, satigrel, on biopsy-proven chronic rejection after kidney transplantation. Transplant Proc. 1997 Feb-Mar;29(1-2):266-71. PubMed PMID: 9122990. 10: Iwai T, Qian S. Clinical evaluation of satigrel in intermittent claudicators. Panminerva Med. 1996 Dec;38(4):243-8. PubMed PMID: 9063033. 11: Nagakura N, Saeki T, Harada K, Yoshitake S, Kobayashi S, Yamanaka T, Saito I. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33. PubMed PMID: 8799481. 12: Fujioka K, Esato K, Furutani A, Akiyama N, Yoshimura K, Takenaka H, Sekido T, Suganuma A, Sagami F. Effect of E5510 on anastomotic intimal hyperplasia and platelet aggregation in dogs. J Cardiovasc Pharmacol. 1996 Jun;27(6):824-30. PubMed PMID: 8761849. 13: Tomikawa M, Hashizume M, Highashi H, Ohta M, Sugimachi K. The role of the spleen, platelets, and plasma hepatocyte growth factor activity on hepatic regeneration in rats. J Am Coll Surg. 1996 Jan;182(1):12-6. PubMed PMID: 8542083. 14: Maruyama S, Uchiyama S, Tohgi H, Hirai S, Ikeda Y, Shinohara Y, Matsuda T, Fujishima M, Kameyama M. A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group. Angiology. 1995 Nov;46(11):999-1008. PubMed PMID: 7486235. 15: Catella F, Reilly MP, Delanty N, Lawson JA, Moran N, Meagher E, FitzGerald GA. Physiological formation of 8-epi-PGF2 alpha in vivo is not affected by cyclooxygenase inhibition. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:233-6. PubMed PMID: 7732842. 16: Nakajima T, Kitajima I, Shin H, Matsumoto W, Soejima Y, Maruyama I. E5510 antagonizes thrombin receptor signals by inhibiting NF-kappa B activation. Biochem Biophys Res Commun. 1994 Sep 15;203(2):1181-7. PubMed PMID: 8093037. 17: Nomoto K, Saeki T, Kogushi M, Kobayashi H, Fujimori T, Yamatsu I. Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro. Jpn J Pharmacol. 1993 Jan;61(1):7-12. PubMed PMID: 8437372. 18: Teraoka S, Naganuma S, Takahashi K, Ota K. Heparin-free hemodialysis with an oral anti-platelet agent. ASAIO J. 1992 Jul-Sep;38(3):M560-3. PubMed PMID: 1457921. 19: Ikeda Y. [Pharmacological aspects of a novel antiplatelet drug, E5510]. Nihon Rinsho. 1992 Feb;50(2):366-71. Japanese. PubMed PMID: 1613992. 20: Iida N. [Inhibitor of thromboxane A2 synthesis as anticoagulant in hemodialysis]. Nihon Rinsho. 1991 Dec;49 Suppl:746-52. Japanese. PubMed PMID: 1839689.